Codexis and Teva to produce generic drug using Codexis biocatalyst
Codexis has signed a licensing agreement with Teva Pharmaceutical Industries to produce a generic product, using a proprietary Codexis biocatalyst.
Codexis has signed a licensing agreement with Teva Pharmaceutical Industries to produce a generic product, using a proprietary Codexis biocatalyst.
Teva, a generic drug manufacturer, is a leading producer of this product, which is one of the largest- selling generic prescription drugs in the US.
Under the agreement, Teva will use the Codexis process for key process steps in the manufacture of this generic medicine, assuming technical milestones are met.
Codexis develops proprietary custom biocatalysts, and its technology is said to contribute to lower pharmaceutical process development and manufacturing costs. Financial terms were not disclosed.
Alan Shaw, Codexis president and chief executive, said: ‘Codexis is very pleased to be partnering Teva, providing high-value technology in the extremely cost-competitive generics marketplace.’
